These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 16728541)

  • 1. Thyrotropin, but not a polymorphism in type II deiodinase, predicts response to paroxetine in major depression.
    Brouwer JP; Appelhof BC; Peeters RP; Hoogendijk WJ; Huyser J; Schene AH; Tijssen JG; Van Dyck R; Visser TJ; Wiersinga WM; Fliers E
    Eur J Endocrinol; 2006 Jun; 154(6):819-25. PubMed ID: 16728541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyroid and adrenal axis in major depression: a controlled study in outpatients.
    Brouwer JP; Appelhof BC; Hoogendijk WJ; Huyser J; Endert E; Zuketto C; Schene AH; Tijssen JG; Van Dyck R; Wiersinga WM; Fliers E
    Eur J Endocrinol; 2005 Feb; 152(2):185-91. PubMed ID: 15745924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients.
    Torlontano M; Durante C; Torrente I; Crocetti U; Augello G; Ronga G; Montesano T; Travascio L; Verrienti A; Bruno R; Santini S; D'Arcangelo P; Dallapiccola B; Filetti S; Trischitta V
    J Clin Endocrinol Metab; 2008 Mar; 93(3):910-3. PubMed ID: 18073314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronobiological hypothalamic-pituitary-thyroid axis status and antidepressant outcome in major depression.
    Duval F; Mokrani MC; Erb A; Gonzalez Lopera F; Alexa C; Proudnikova X; Butucaru I
    Psychoneuroendocrinology; 2015 Sep; 59():71-80. PubMed ID: 26036452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of treatment response by HPA-axis and glucocorticoid receptor polymorphisms in major depression.
    Brouwer JP; Appelhof BC; van Rossum EF; Koper JW; Fliers E; Huyser J; Schene AH; Tijssen JG; Van Dyck R; Lamberts SW; Wiersinga WM; Hoogendijk WJ
    Psychoneuroendocrinology; 2006 Nov; 31(10):1154-63. PubMed ID: 17034955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type 2 Deiodinase Thr92Ala Polymorphism and Aging Are Associated with a Decreased Pituitary Sensitivity to Thyroid Hormone.
    Luongo C; De Stefano MA; Ambrosio R; Volpe F; Porcelli T; Golia V; Bellevicine C; Troncone G; Masone S; Damiano V; Matano E; Klain M; Schlumberger M; Salvatore D
    Thyroid; 2023 Mar; 33(3):294-300. PubMed ID: 36680751
    [No Abstract]   [Full Text] [Related]  

  • 7. MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression.
    Mihaljevic Peles A; Bozina N; Sagud M; Rojnic Kuzman M; Lovric M
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1439-44. PubMed ID: 18550244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The type 2 deiodinase ORFa-Gly3Asp polymorphism (rs12885300) influences the set point of the hypothalamus-pituitary-thyroid axis in patients treated for differentiated thyroid carcinoma.
    Hoftijzer HC; Heemstra KA; Visser TJ; le Cessie S; Peeters RP; Corssmit EP; Smit JW
    J Clin Endocrinol Metab; 2011 Sep; 96(9):E1527-33. PubMed ID: 21715540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyroid autoimmunity and treatment response to escitalopram in major depression.
    Eller T; Metsküla K; Talja I; Maron E; Uibo R; Vasar V
    Nord J Psychiatry; 2010 Aug; 64(4):253-7. PubMed ID: 20088751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thr92Ala polymorphism in the type 2 deiodinase is not associated with T4 dose in athyroid patients or patients with Hashimoto thyroiditis.
    Heemstra KA; Hoftijzer HC; van der Deure WM; Peeters RP; Fliers E; Appelhof BC; Wiersinga WM; Corssmit EP; Visser TJ; Smit JW
    Clin Endocrinol (Oxf); 2009 Aug; 71(2):279-83. PubMed ID: 19018782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine.
    Lin KM; Tsou HH; Tsai IJ; Hsiao MC; Hsiao CF; Liu CY; Shen WW; Tang HS; Fang CK; Wu CS; Lu SC; Kuo HW; Liu SC; Chan HW; Hsu YT; Tian JN; Liu YL
    Pharmacogenomics; 2010 Nov; 11(11):1535-43. PubMed ID: 21121774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms in type 2 deiodinase are not associated with well-being, neurocognitive functioning, and preference for combined thyroxine/3,5,3'-triiodothyronine therapy.
    Appelhof BC; Peeters RP; Wiersinga WM; Visser TJ; Wekking EM; Huyser J; Schene AH; Tijssen JG; Hoogendijk WJ; Fliers E
    J Clin Endocrinol Metab; 2005 Nov; 90(11):6296-9. PubMed ID: 16144953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fasting-induced increase in type II iodothyronine deiodinase activity and messenger ribonucleic acid levels is not reversed by thyroxine in the rat hypothalamus.
    Diano S; Naftolin F; Goglia F; Horvath TL
    Endocrinology; 1998 Jun; 139(6):2879-84. PubMed ID: 9607797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.
    Gex-Fabry M; Eap CB; Oneda B; Gervasoni N; Aubry JM; Bondolfi G; Bertschy G
    Ther Drug Monit; 2008 Aug; 30(4):474-82. PubMed ID: 18641553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucocorticoids and relapse of major depression (dexamethasone/corticotropin-releasing hormone test in relation to relapse of major depression).
    Appelhof BC; Huyser J; Verweij M; Brouwer JP; van Dyck R; Fliers E; Hoogendijk WJ; Tijssen JG; Wiersinga WM; Schene AH
    Biol Psychiatry; 2006 Apr; 59(8):696-701. PubMed ID: 16368077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical application of paroxetine for tapering benzodiazepine use in non-major-depressive outpatients visiting an internal medicine clinic.
    Nakao M; Takeuchi T; Nomura K; Teramoto T; Yano E
    Psychiatry Clin Neurosci; 2006 Oct; 60(5):605-10. PubMed ID: 16958945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
    Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Gao K; Cui X; Nierenberg AA;
    J Clin Psychopharmacol; 2010 Aug; 30(4):357-64. PubMed ID: 20571433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subclinical hypothyroidism in early childhood: a frequent outcome of transient neonatal hyperthyrotropinemia.
    Calaciura F; Motta RM; Miscio G; Fichera G; Leonardi D; Carta A; Trischitta V; Tassi V; Sava L; Vigneri R
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3209-14. PubMed ID: 12107226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of thyroid function and polymorphisms in the type 2 deiodinase on blood pressure: the Rotterdam Study and the Rotterdam Scan Study.
    van der Deure WM; Peeters RP; Uitterlinden AG; Hofman A; Breteler MM; Witteman J; Visser TJ
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):137-44. PubMed ID: 19178511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.